Charles Schwab
RLMD icon

Charles Schwab’s Relmada Therapeutics RLMD Stock Holding History

Charles Schwab’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.96M Buy
282,717
+229,636
+433% +$1.6M ﹤0.01% 2798
2026
Q1 		$369K Hold
53,081
– – ﹤0.01% 3197
2025
Q4 		$256K Buy
+53,081
New +$178K ﹤0.01% 3310
2024
Q4 		– Sell
-12,505
Closed -$40.5K – 3511
2024
Q3 		$40.5K Hold
12,505
– – ﹤0.01% 3434
2024
Q2 		$37.5K Hold
12,505
– – ﹤0.01% 3543
2024
Q1 		$58.1K Hold
12,505
– – ﹤0.01% 3354
2023
Q4 		$51.8K Hold
12,505
– – ﹤0.01% 3401
2023
Q3 		$37.5K Hold
12,505
– – ﹤0.01% 3432
2023
Q2 		$30.8K Sell
12,505
-61,410
-83% -$170K ﹤0.01% 3502
2023
Q1 		$167K Buy
73,915
+12,505
+20% +$43.1K ﹤0.01% 3184
2022
Q4 		$214K Sell
61,410
-9,105
-13% -$80K ﹤0.01% 3175
2022
Q3 		$2.61M Sell
70,515
-1,991
-3% -$55.2K ﹤0.01% 2505
2022
Q2 		$1.38M Buy
72,506
+5,510
+8% +$120K ﹤0.01% 2684
2022
Q1 		$1.81M Buy
66,996
+21,621
+48% +$447K ﹤0.01% 2678
2021
Q4 		$1.02M Buy
45,375
+4,118
+10% +$91.6K ﹤0.01% 2903
2021
Q3 		$1.08M Sell
41,257
-57,910
-58% -$1.55M ﹤0.01% 2847
2021
Q2 		$3.17M Buy
99,167
+4,605
+5% +$160K ﹤0.01% 2566
2021
Q1 		$3.33M Buy
94,562
+1,734
+2% +$60.7K ﹤0.01% 2492
2020
Q4 		$2.98M Buy
92,828
+3,392
+4% +$117K ﹤0.01% 2462
2020
Q3 		$3.37M Sell
89,436
-620
-0.7% -$24K ﹤0.01% 2268
2020
Q2 		$4.03M Buy
90,056
+36,728
+69% +$1.55M ﹤0.01% 2127
2020
Q1 		$1.82M Buy
53,328
+4,141
+8% +$167K ﹤0.01% 2309
2019
Q4 		$1.92M Buy
+49,187
New +$1.49M ﹤0.01% 2434

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Charles Schwab's RLMD Position: Q2 2026 in Review

Charles Schwab increased its Relmada Therapeutics (RLMD) stake by 433% in Q2 2026, buying an estimated $1.6M and bringing the position to 282,717 shares worth $1.96M. The position accounts for ﹤0.01% of the portfolio, ranked #2798.

Charles Schwab first reported a position in RLMD in Q4 2019 and has held it in 23 quarters since. The position peaked at $4.03M in Q2 2020. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Charles Schwab held 282,717 shares of Relmada Therapeutics worth $1.96M as of Q2 2026.
  • Charles Schwab bought 229,636 Relmada Therapeutics shares in Q2 2026, an estimated $1.6M.
  • Relmada Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2798 holding.
  • Charles Schwab first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 23 quarters since.
  • Charles Schwab's Relmada Therapeutics position peaked at $4.03M in Q2 2020.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.